title: [Fondaparinux as an alternative anticoagulant in heparin-induced thrombocytopenia in the patient with a ventricular assist device].
abstract: Heparin-induced thrombocytopenia is a reaction associated with the use of this drug. It occurs in up to 3% of patients treated for at least 5 days. Its treatment is to stop the heparin, and according to patient needs, replace it with another anticoagulant. We present a patient who, after a heart transplant, and the need for a ventricular assist device, required anticoagulation. The patient developed heparin-induced thrombocytopenia. Heparin was stopped and anticoagulation was replaced by fondaparinux. The peri-operative complications and the management of the coagulation are described.
authors.affiliation: Unidad de Anestesia Cardiovascular, Servicio de Anestesiología y Reanimación, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: vcegarra@santpau.cat.
authors.forename: V
authors.initials: V
authors.lastname: Cegarra-Sanmartín
authors.forename: P
authors.initials: P
authors.lastname: Paniagua
authors.forename: J
authors.initials: J
authors.lastname: Galán
authors.forename: C
authors.initials: C
authors.lastname: Muñoz
authors.forename: M V
authors.initials: MV
authors.lastname: Moral
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006353:Heart-Assist Devices; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux